Viatris Inc（VTRS）の決算・業績分析
Viatris Incの2025年有価証券報告書をAI分析。売上高$14.3B(-3.0%)。営業利益-$2.7B。Health Care。
目次
Viatris Incの2025年度 業績サマリー
Viatris Inc（証券コード: VTRS）の2025年度決算・業績分析。売上高は$14.3B（前年比-3.0%）。営業利益は-$2.7B（前年比-26467.3%）。純利益は-$3.5B（前年比-454.2%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
Viatris Incの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Operating income surged +4849.7% YoY to $1.6B (XBRL), driven by cost optimization and efficiency gains despite a 9.0% YoY revenue decline to $16.2B (XBRL).
- Net debt reached $14.9B (3.2x EBITDA) (XBRL), reflecting high leverage despite strong operating cash flow of $3.0B (XBRL).
- Net income jumped +263.8% YoY to $2.1B (XBRL), with net margin expanding to 12.8% (XBRL) due to improved profitability and cost control.
Viatris Incの売上高変化の要因
- •Revenue declined 9.0% YoY to $16.2B (XBRL), down from $17.8B in FY2023. Historical data shows a peak in FY2023, followed by a drop in FY2024 and further decline in FY2025 ($15.4B). The 5-year revenue CAGR of +6.4% (XBRL) contrasts with the recent downturn, potentially due to divestitures or market pressures. No segment-specific revenue data is available (XBRL).
Viatris Incの営業利益変化の要因
- •Gross margin improved to 40.1% (XBRL), with gross profit at $6.5B. Operating margin rose to 10.0% (XBRL), reflecting a dramatic increase in operating income (+4849.7% YoY to $1.6B) (XBRL). Net margin expanded to 12.8% (XBRL), driven by a 263.8% YoY jump in net income to $2.1B (XBRL). The 5-year operating income CAGR of -3.3% (XBRL) contrasts with FY2024’s surge, suggesting a turnaround in cost efficiency.
Viatris Incの事業リスクと対応
Strategic risks from divestitures/acquisitions integration and pricing pressures (10-K).
Operational risks from regulatory compliance and competition strategies (10-K).
Compliance risks related to anti-corruption laws (US FCPA, UK Bribery Act) and IP litigation (10-K).
Financial risks from high debt ($16.2B long-term debt) and currency fluctuations (10-K).
Operational risks from R&D failures and product market acceptance (10-K).
Regulatory pressures from competitors and government pricing controls (10-K).
Viatris Incの事業内容
Viatris Inc (VTRS) is a global healthcare company supplying medicines to 1 billion patients annually, generating revenue through generics, branded products, and innovative medicines (10-K). With 32,000 employees, the company operates in 165+ countries and leverages a global supply chain, 26 manufacturing sites, and a portfolio of 1,400+ approved molecules (10-K). Key segments include generics (including complex products), iconic brands, and innovative medicines, though it has divested segments like OTC and API manufacturing in India (10-K). Competitive advantages include strong cash flow ($3.0B operating CF) and financial health (43.0% equity ratio) (XBRL).
Viatris IncのAI業績分析レポート（2024年度）
Viatris Inc (VTRS) Annual Report Analysis FY2024
Highlights
Business Overview
Viatris Inc is a global healthcare company supplying medicines to 1 billion patients annually, generating revenue through generics, branded products, and innovative medicines (10-K). With 32,000 employees, the company operates in 165+ countries and leverages a global supply chain, 26 manufacturing sites, and a portfolio of 1,400+ approved molecules (10-K). Key segments include generics, iconic brands, and innovative medicines, though it has divested segments like OTC and API manufacturing in India (10-K). Competitive advantages include strong cash flow ($3.0B operating CF) and financial health (43.0% equity ratio) (XBRL).
Revenue Analysis
Revenue declined 9.0% YoY to $16.2B (XBRL), down from $17.8B in FY2023. Historical data shows a peak in FY2023, followed by a drop in FY2024 and further decline in FY2025 ($15.4B). The 5-year revenue CAGR of +6.4% (XBRL) contrasts with the recent downturn, potentially due to divestitures or market pressures. No segment-specific revenue data is available (XBRL).
Profitability Analysis
Gross margin improved to 40.1% (XBRL), with gross profit at $6.5B. Operating margin rose to 10.0% (XBRL), reflecting a dramatic increase in operating income (+4849.7% YoY to $1.6B) (XBRL). Net margin expanded to 12.8% (XBRL), driven by a 263.8% YoY jump in net income to $2.1B (XBRL). The 5-year operating income CAGR of -3.3% (XBRL) contrasts with FY2024’s surge, suggesting a turnaround in cost efficiency.
Balance Sheet Analysis
Total assets declined to $47.7B (XBRL), with total equity at $20.5B (XBRL). The equity ratio of 43.0% (XBRL) and D/E ratio of 1.33x (XBRL) indicate moderate leverage. Current ratio of 1.67x (XBRL) suggests strong short-term liquidity. However, net debt of $14.9B (3.2x EBITDA) (XBRL) highlights significant long-term financial obligations ($16.2B long-term debt) (XBRL).
Cash Flow Analysis
Operating cash flow remained stable at $3.0B (XBRL), with FCF of $2.6B after $406M in CapEx (XBRL). Investing cash flow was $1.5B (XBRL), while financing cash flow was -$3.9B (XBRL) due to debt servicing. No share repurchases occurred (XBRL). CapEx intensity of 2.5% (XBRL) and CapEx/D&A ratio of 0.13x (XBRL) suggest conservative capital spending.
Working Capital Analysis
Receivables Days: 83 days (XBRL), Inventory Days: 130 days (XBRL), Asset Turnover: 0.34x (XBRL). No data on payables days or cash conversion cycle (CCC) is available (XBRL).
Risks
Outlook
N/A — no management guidance or forward-looking trends are explicitly mentioned in the 10-K or XBRL data (XBRL).
Health Careの企業一覧
Viatris Incと同じ「Health Care」セクターの企業